Skip to content

EACS: Once-a-day Kaletra can be risky

EACS: Hospital admissions and appointments predict subsequent HIV diagnosis and death

EACS: One in five UK patients remains on failing therapy for over a year

Bevirimat 300mg oral solution dose does well in study

Boosted saquinavir as good as Kaletra, Gemini study shows

Once-daily nevirapine doesn't improve adherence, may increase risk of treatment break and resistance

Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines

Swiss find no increase in transmitted resistance over past decade

Fosamprenavir: US approves once-daily dose with less ritonavir boosting